Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting.

Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting.

<h4>Purpose</h4>To establish a baseline for care and overall survival (OS) based upon contemporary first-line treatments prescribed in the era before the introduction of immune checkpoint inhibitors, for people with metastatic non-small cell lung cancer (NSCLC) without common actionable...

Celý popis

Podrobná bibliografie
Hlavní autoři: Amy P Abernethy, Ashwini Arunachalam, Thomas Burke, Caroline McKay, Xiting Cao, Rachael Sorg, David P Carbone
Médium: Článek
Jazyk:English
Vydáno: Public Library of Science (PLoS) 2017-01-01
Edice:PLoS ONE
On-line přístup:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0178420&type=printable

Internet

https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0178420&type=printable

Podobné jednotky